OBJECTIVE:To provide reference for drug registration declaration. METHODS:The disapproval comments of Chi-na Food and Drug Administration on the declared drugs in Guangdong Province in 2015 were collected,existing problems in cur-rent drug registration declaration in clinical trials stage and registered production stage were analyzed. And suggestions were put for-ward based on relevant policies and regulations. RESULTS & CONCLUSIONS:Reasons for the rejection of declaring chemical drugs in clinical trials stage mainly focused on that there had been imported drugs applied for registration or new drugs entering monitoring period. While pharmacy research quality defects,especially insufficient research in impurities and relevant materials, are the main problems of declaring clinical trials and production. In terms of clinical trail declaration,applicant should respond to new drug registration classification reform,strengthen original innovation development;the development of biological products should establish comprehensive and effective evaluation system to form superior technology and products. In terms of drug registra-tion production declaration,related departments or drug manufacturers should enhance the evaluation for drug form and specifica-tions design,and generic drugs should pay attention to the consistency evaluation with the original research drugs. Besides,the above problems can be solved by conducting scientific and feasible research methods for impurities and related material,and pay at-tention to enlarging research of forward-looking production technology.%目的:为药品注册申报提供参考.方法:收集2015年国家食品药品监督管理总局对广东省申报药品不予批准的审批意见,分析临床试验和注册生产两个阶段中药品注册申报存在的问题,并根据相关的政策法规提出建议.结果与结论:化学药申报临床试验阶段被退审的原因主要集中在已有进口药品注册申请批准或该新药进入监测期;而药学研究质量缺陷,特别是杂质、有关物质研究不充分是申报临床试验和申报生产中的主要问题.针对临床试验申报,申请人应适应新的药品注册分类改革,加强原始创新药物研制,生物制品开发应建立全面有效的生物制品评价体系,形成优势技术和产品;针对注册生产申报,相关部门或药物生产企业应加强对药品剂型和规格设计的合理性评价,仿制药应注重与原研药品的一致性评价.除此之外,还可通过建立科学可行的杂质、有关物质研究方法,注重前瞻性生产工艺的放大研究等解决上述问题.
展开▼
